drugset
drugset / Trial / NCT01098877

First In Human Study Of Increasing Oral Doses Of PF-04634817

NCT01098877 ↗

Phase 1 Completed 27 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

The study will evaluate the hypothesis that at doses and plasma concentrations which affect pharmacodynamic markers of activity at the chemokine receptors, CCR2 and CCR5, the compound is safe and well tolerated. It will also evaluate the hypothesis that the pharmacokinetic profile is robust and consistent with a once or twice a day therapeutic administration.

Timeline

Start
2010-04
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04634817 Small molecule 1 mg Oral
Subject PF-04634817 Small molecule 3 mg Oral
Subject PF-04634817 Small molecule 10 mg Oral
Subject PF-04634817 Small molecule 30 mg Oral
Subject PF-04634817 Small molecule 100 mg Oral
Subject PF-04634817 Small molecule 300 mg Oral
Subject PF-04634817 Small molecule 600 mg Oral
Subject PF-04634817 Small molecule 900 mg Oral

Indications

No indication recorded.